Application of lauromacrogol combined hyaluronic acid in preparation of medicine for treating venous malformed foam sclerosis

A hyaluronic acid and venous malformation technology, which is applied in drug combination, drug delivery, and pharmaceutical formulations, can solve the problems of limited therapeutic effect on venous malformation

Inactive Publication Date: 2014-05-21
SHANDONG UNIV QILU HOSPITAL
View PDF1 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the drugs that can be used to prepare foam sclerosing agents at home and abroad are mainly sodium morrhuate and lauromacrogol. The liquid sclerosing agent is prepared into a foam according to the Tessari method and air at a ratio of 1:4. The half-life of the foam is about 120 seconds. Clinical findings Limited use in the treatment of venous malformations

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of lauromacrogol combined hyaluronic acid in preparation of medicine for treating venous malformed foam sclerosis
  • Application of lauromacrogol combined hyaluronic acid in preparation of medicine for treating venous malformed foam sclerosis
  • Application of lauromacrogol combined hyaluronic acid in preparation of medicine for treating venous malformed foam sclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Embodiment 1 Hyaluronic acid is combined with lauromacrogol to make a foam hardener and apply it

[0022] The preparation method of foam hardening agent is as follows:

[0023] Use one syringe to extract lauromacrogol, hyaluronic acid and water for injection, shake to mix evenly, use another syringe to extract sterile air, connect the two syringes through a medical three-way valve, follow the Tessari method (the most classic method for preparing foam sclerosing agents) , the most commonly used method) several times before and after bolus mixing to form a uniform and stable foam; among them, the volume ratios of lauromacrogol, hyaluronic acid, water for injection, and sterile air are shown in Table 1 (four experimental groups, a control group).

[0024] Table 1 Experimental grouping

[0025]

[0026] Note:

[0027] Volume unit mL

[0028] Lauromacrogol used in the present invention is commercially available, chemical name: polyoxyethylene lauryl ether, Shaanxi Tia...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of lauromacrogol combined hyaluronic acid in preparation of a medicine for treating venous malformed foam sclerosis. The lauromacrogol combined hyaluronic acid is prepared to form a foam hardening agent in particular application. The preparation method of lauromacrogol combined hyaluronic acid comprises the following steps: pumping lauromacrogol, hyaluronic acid and injection water by using an injector, and uniformly shaking and mixing; pumping sterile air by the other injector, wherein the two injectors are connected by a medical tee-joint valve; and feeding a plurality of times in a Tessari method, and mixing to form uniform and stable foam. According to the application, the foam hardening agent is prepared from the lauromacrogol combined hyaluronic acid and used for treating venous malformation, so that the half time of foam can be remarkably prolonged, and the curative effect can be improved. Currently, the method is successfully adopted in the stomatological department of Qilu Hospital of Shandong University, 20 cases with large-area venous malformation in maxillofacial region are treated, and the clinical effect is remarkable.

Description

technical field [0001] The invention relates to the application of hyaluronic acid combined with lauromacrogol in the preparation of foam sclerosing medicine for treating venous malformation. Background technique [0002] Venous malformation is a congenital developmental malformation with an incidence rate of about 1:5000-10000, about 40% of which occur in the head and neck. It not only affects the face, but also causes pain, ulcers, bleeding or compression and invades adjacent tissue structures, followed by Affect language swallowing and breathing function, and even have the risk of suffocation death. [0003] Pathologically, venous malformations are composed of dilated veins of different sizes. The lesions grow in proportion to the body, develop gradually throughout life, and will not subside by themselves. Treatment options include laser, sclerotherapy, and surgery. Sclerotherapy is to inject chemical drugs into the lumen of the deformed vein to occlude the deformed vei...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/00A61K31/765A61K47/36A61P9/14
Inventor 陈安威刘少华刘怡然李凯
Owner SHANDONG UNIV QILU HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products